MACK - Merrimack Pharmaceuticals, Inc.
| 前收市價 | 12.48 |
| 開市 | 12.47 |
| 買盤 | 12.31 x 800 |
| 賣出價 | 12.76 x 900 |
| 今日波幅 | 12.45 - 12.56 |
| 52 週波幅 | 3.00 - 13.66 |
| 成交量 | |
| 平均成交量 | 74,330 |
| 市值 | 178.679M |
| Beta 值 (5 年，每月) | 1.80 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -0.12 |
| 業績公佈日 | 2023年8月02日 - 2023年8月07日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 2019年12月13日 |
| 1 年預測目標價 | 4.00 |
Insider Monkey12 Best Performing Biotech Stocks in 2022
In this article, we discuss 12 best performing biotech stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing Biotech Stocks in 2022. Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in […]
BenzingaWhy Merrimack Shares Are Surging Over 200% Today?
Ipsen SA (OTC: IPSEY) announced that the Phase 3 NAPOLI 3 trial of Onivyde plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its primary endpoint. The combination therapy demonstrated a clinically meaningful and statistically significant improvement in overall survival compared to nab-paclitaxel plus gemcitabine in 770 previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Progression-free survival (PFS) also showed significant improvement ov
BenzingaMerrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
Merrimack Pharmaceuticals Inc's (NASDAQ: MACK) partner announced that Ipsen SA (OTC: IPSEY) reported a primary analysis of the results of the Phase 3 trial of Onivyde (irinotecan liposomal injection)for second-line small cell lung cancer (SCLC). The study did not meet the primary endpoint of overall survival in patients treated with Onivyde versus topotecan. However, a doubling of the secondary endpoint of objective response rate (ORR) in favor of Onivyde was observed. The safety and tolerabilit